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Abstract: Treatment-resistant depression (TRD) is a common occurrence in clinical practice. 
Up to 30% of patients with major depression do not respond to conventional antidepressant 
treatment, while a significantly greater number of patients experience only partial symptom 
reduction. Numerous strategies may be applied by the practicing clinician to overcome 
limitations in the effectiveness of antidepressant monotherapy, including combining drug 
treatment with evidence-supported psychotherapies, combining antidepressants (combination 
pharmacotherapy), and combining antidepressants with other non-antidepressant psychotropic 
medications (augmentation treatment). One such augmentation strategy, the combination of the 
selective serotonin reuptake inhibitor, fluoxetine (FLX), with the atypical antipsychotic drug, 
olanzapine (OLZ), is supported by the results of four randomized, double-blind, acute phase 
studies of patients who had responded inadequately to antidepressant monotherapy. In each 
study, the FLX/OLZ combination caused rapid reduction in Montgomery-Asberg Depression 
Rating scale scores, with two of the four studies showing significantly greater improvement 
than antidepressant monotherapy at study endpoint. Effects of the FLX/OLZ combination were 
strongest in cases where failure to respond to two antidepressants prior to randomization was 
established during the current depressive episode. The FLX/OLZ combination was well-tolerated; 
however, body weight gain and increases in prolactin were greater than that of the antidepres-
sant monotherapy groups, and were comparable to that of OLZ monotherapy. While effective 
during acute-phase treatment, questions remain regarding the long-term efficacy and safety of 
FLX/OLZ relative to antidepressant monotherapy and other combination strategies. Efforts 
aimed at determining the placement of FLX/OLZ among the available options for addressing 
TRD are limited by lack of comparison and sequential treatment studies. Important aspects of 
study design and directions for future research are discussed.
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Introduction
In the last two decades, there has been a marked increase in the number of antidepressant 
medications available for the treatment of major depressive disorder (MDD). In spite of 
this, it has become increasingly evident that the effectiveness of antidepressant mono-
therapy for MDD is much more modest than what was once believed. For example, 
a recent meta-analysis of all published double-blind placebo controlled antidepressant 
trials reported an antidepressant response rate of 53%.1 Although this rate of response 
was significantly greater than the placebo response rate (36%, P  0.05), these results 
have challenged the widely accepted anticipated response rates of 60% to 70% reported 
in prior reviews of controlled studies.2Neuropsychiatric Disease and Treatment 2009:5 370
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Rates of acute and sustained symptom remission on 
antidepressant monotherapy are even lower, both under ideal 
treatment conditions that characterize randomized controlled 
trials, and in actual clinical treatment settings.3–5 For instance, 
only about 30% of patients achieved clinical remission in the 
first phase of the landmark Sequenced Treatment Alterna-
tives to Relieve Depression (STAR*D) study after 12 weeks 
of citalopram monotherapy.6 Only about 70% of patients 
achieved remission after multiple rounds of medications 
or cognitive therapy, and the majority of patients relapsed 
within the first year following remission.7 The importance 
of this point rests in the fact that the persistence of residual 
depressive symptoms is associated with substantial disability 
and increased risk of a full depressive relapse, even among 
patients who achieve a positive antidepressant response 
and remain in active treatment.8,9 As such, the majority of 
antidepressant-treated patients with major depression either 
fail to improve meaningfully or experience positive but only 
partial improvement. Clearly, there is an urgent need to 
develop safe and more effective treatments for major depres-
sive disorder (MDD).
Until such treatments become available, numerous 
strategies may be applied by the practicing clinician to 
overcome limitations in the effectiveness of antidepressant 
monotherapy. In broad terms, these include combining 
drug treatment with evidence-supported psychotherapies,10 
combining antidepressants with different pharmacological 
profiles (combination pharmacotherapy), and combining 
antidepressants with psychotropic medications that are not 
antidepressants (augmentation treatment).11,12 One such 
augmentation treatment approach is the combination of anti-
depressants with atypical antipsychotic drugs. There is now 
controlled evidence supporting the short-term effectiveness 
of atypical antipsychotic augmentation of antidepressants, 
including cases of difficult to treat MDD with and without 
psychotic features.13–15 In addition, one atypical antipsychotic 
drug, aripiprazole, has a US Food and Drug Administration 
(FDA) indication as an adjunctive therapy for suboptimal 
antidepressant response in patients with MDD,16 and one 
selective serotonin reuptake inhibitor (SSRI)/atypical anti-
psychotic combination (fluoxetine + olanzapine) is FDA 
approved for acute bipolar depression.17 Enthusiasm for this 
approach is tempered by a lack of long-term effectiveness 
data, as well as long-term metabolic safety and tolerability 
concerns for many of these agents. This review is focused on 
the therapeutic rationale for and clinical evidence supporting 
the combination of fluoxetine and olanzapine for treatment-
resistant MDD (TRD). Characteristics and implications 
of key design issues in each of the reviewed studies will 
be emphasized.
Mechanisms of action
Neurotransmitter dysfunction 
in major depression
A substantial body of evidence indicates that dysfunction 
in serotonin (5-hydroxytryptamine, 5-HT), norepinephrine 
(NE) and, to a lesser degree, dopamine (DA) neurotrans-
mission are involved in the pathophysiology of major 
depression,18–20 and that intact 5-HT and NE neurotrans-
mitter systems are needed in order to maintain positive 
clinical response to antidepressant medications. By now, 
it is also apparent that early theories that sought to explain 
the signs and symptoms of major depression solely on the 
basis of 5-HT and NE depletion have not provided a unify-
ing neurobiological theory explaining why major depres-
sion occurs or how antidepressants exert their therapeutic 
effects. Nevertheless, the monoaminergic neurotransmitter 
systems have served as the most important pharmaco-
logical targets from antidepressant drug development 
over the last four decades.21 Nearly all currently available 
antidepressant drugs act as potentiators of monoamine 
neurotransmission, either by inhibition of enzymes needed 
for monoamine degradation, or by blocking monoamine 
reuptake sites.
In recent years, a more sophisticated understanding of 
the pathophysiology of major depression has emerged that 
focuses on dysregulation of 5-HT and NE transmission rather 
than monoamine depletion, per se. Abnormalities in the 
functional activity of numerous brain regions have been iden-
tified in depressed patients using functional neuroimaging, 
including cortical and limbic structures that are critical for 
regulation of mood, emotional processing, cognitive and 
psychomotor functioning, and motivation,22–24 all common 
symptoms of depression. Importantly, each of these regions 
receive serotonergic, noradrenergic and/or dopaminergic 
projections,25 and abnormalities in several of these regions 
identified on neuroimaging have been shown to resolve 
following treatment with antidepressants that potentiate 5-HT 
and/or NE neurotransmission.26–29
Limitations of fluoxetine monotherapy
Monoamine neurotransmission in these key brain regions 
is tightly regulated, in part, by functional activity of several 
critical postsynaptic neuroreceptors that are not acted 
upon directly by SSRIs and other first-line antidepressants. Neuropsychiatric Disease and Treatment 2009:5 371
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Fluoxetine (FLX) and other SSRIs occupy 5-HT reuptake 
pumps with relatively high affinity and specificity; however, 
their pharmacological activity is limited, for all practical 
purposes, to reuptake pump blockade.30,31 This poses three 
potential limitations that may result in a lack of meaningful 
clinical response to monotherapy with FLX for some patients. 
First, FLX does not act as a pharmacological agonist and 
cannot directly activate postsynaptic receptors that are impor-
tant for the control of monoamine functioning in the central 
nervous system (CNS). Instead, FLX is dependent almost 
entirely on intact presynaptic serotonergic functioning.32 
Second, FLX has only negligible effects on NE and DA 
reuptake, and does not directly enhance noradrenergic or 
dopaminergic neurotransmission.30 Furthermore, continu-
ous SSRI treatment is associated with suppression of locus 
coeruleus firing,33–35 resulting in decreased NE transmission. 
This is believed to occur as a consequence of enhanced acti-
vation of excitatory postsynaptic 5-HT2A receptors located 
on inhibitory GABAergic interneurons that synapse with 
NE neurons.36 Third, SSRIs have been shown to suppress 
ventral tegmental area activity, and therefore reduce DA 
neurotransmission,37,38 possibly by a 5-HT2C dependent 
mechanism.39–41 Thus, FLX and other SSRIs may not be 
able to fully optimize central monoaminergic functioning as 
stand-alone therapies. These limitations cannot be overcome 
by increases in medication dosage alone.
Augmentation with atypical 
antipsychotics: focus on olanzapine
The atypical antipsychotics are a pharmacologically 
heterogenous group of drugs. Although each is associated 
with a unique profile of neuroreceptor binding activity, all 
share the properties of high-potency postsynaptic 5-HT2A 
antagonism with relatively lower potency dopamine D2 
receptor antagonism (or D2 partial agonist effects, in the 
case of aripiprazole). Importantly, the atypical antipsychotic 
drug, olanzapine (OLZ), is pharmacologically active at other 
neuroreceptors that are important for optimizing central 
monoamine functioning (Table 1). As such, adjunctive 
therapy with OLZ may be a practical means of overcoming 
many of the mechanistic limitations of FLX monotherapy, 
and improving clinical response to FLX in patients with 
treatment resistant major depression.
For example, 5-HT2A blockade results in numerous 
effects that are relevant to the activity of FLX. In the presence 
of 5-HT reuptake inhibition, 5-HT2A receptor antagonism 
has been shown to enhance 5-HT and NE release in rodents.42 
In preclinical models, chronic administration of FLX alone 
Table 1 Selected serotonergic neuroreceptor targets of olanzapine with potential relevance for antidepressant augmentation in treatment-
resistant depression13,42,45–47
Neuroreceptor Pharmacological activity Functional consequence Possible benefit in TRD
5-HT1A Agonist enhance Ne release in PFC and NAcc improved cognitive functioning
increase DA release in frontal cortex  
and NAcc
improved mood, cognitive functioning and  
motivational drive
Overcome SSri induced suppression of central   
DA activity
5-HT2A Antagonist enhance 5-HT and Ne releasea reverse SSri induced suppression of locus  
coeruleus firing
enhance DA release in PFCb improved regulation of mood and cognitive  
functioning
Overcome SSri induced suppression of central   
DA activity
5-HT2C Antagonist enhance Ne release in PFC and NAcc improved cognitive functioning
increase DA release in frontal cortex  
and NAcc
improved mood, cognitive functioning and  
motivational drive
Overcome SSri induced suppression of central   
DA activity
5-HT6 Antagonist enhance DA release in PFC improved cognitive functioning
         Overcome SSri induced suppression of central   
DA activity
ain presence of 5-HT reuptake inhibition.
bin presence of weak D2 receptor antagonism.
Abbreviations:   TrD, treatment-resistant depression; DA, dopamine; Ne, norepinephrine; PFC, ; SSri, selective serotonin reuptake inhibitor; NAcc, ;Neuropsychiatric Disease and Treatment 2009:5 372
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suppressed locus coeruleus neuronal activity while acutely 
administered OLZ significantly increased locus coeruleus 
firing.43 The combination of FLX + OLZ, however, resulted in 
enhanced locus coeruleus firing during both acute and chronic 
administration.43 Increased NE release may be predicted 
by antagonism of the aforementioned 5-HT2A dependent 
reduction in NE neuronal firing, while increased NE release 
may then enhance 5-HT neuronal firing via activation of 
postsynaptic α-1 adrenergic receptors in the raphe nuclei.42 
In addition, OLZ-associated postsynaptic 5-HT2C antago-
nism and 5-HT1A activation have also been shown to increase 
NE release in the prefrontal cortex.44 Thus, the combination 
of FLX + OLZ may result in a greater degree of serotonergic 
activity than would be expected with FLX alone, and may 
also reverse FLX-associated NE suppression.
Interactions at serotonin receptors also have important 
effects on DA neurotransmission. Blockade of 5-HT2A and 
5-HT6 receptors, combined with weak D2 receptor antago-
nism, have both been shown to enhance DA release to a 
greater degree than blockade of either receptor alone.45,46 
In addition to increasing NE efflux, OLZ effects on 5-HT2C 
and 5-HT1A receptors have been shown to increase DA 
release in the frontal cortex and nucleus accumbens,44,47 
brain regions that are tied to cognitive functioning and 
motivational drive.48 Clinically, the 5-HT2A antagonists, 
trazodone and nefazodone, and the 5-HT1A partial agonist, 
gepirone, have all shown antidepressant effects in clinical 
trials.49–51 Augmentation of FLX with OLZ may therefore 
provide a means of enhancing DA activity in brain regions 
implicated in the pathophysiology of major depression that 
would not be possible with FLX alone, an effect that may 
be strong enough to overcome FLX-associated suppres-
sion of central DA activity and improve antidepressant 
response.
Finally, there has been considerable interest in the role of 
brain derived neurotrophic factor (BDNF), one of a number 
of neurotrophic factors involved in neuronal maintenance 
and survival,52 in the both pathogenesis of major depression 
and the clinical response to antidepressants.53 BDNF has 
been shown to play an important role in the susceptibility of 
depression-prone patients to the negative effects of stress.54 
In post-mortem brains of depressed patients, low levels of 
hippocampal and prefrontal BDNF have been documented.53 
Abnormally low levels of serum BDNF have also been found 
in patients with major depression.55 It is noteworthy that 
long-term exposure to FLX and other antidepressants has 
been shown to increase BDNF production,56 and that stress-
induced reduction in levels of BDNF and Bcl-2, another 
neurotrophic factor, may be blocked with long-term treatment 
with OLZ.57 These results suggest that the combination of 
FLX + OLZ may have synergistic effects on neurotrophin 
activity, thereby providing an alternative mechanism by 
which OLZ may enhance the clinical antidepressive effects 
of FLX.
Efficacy in clinical trials
results of acute phase studies in TrD
Five randomized, controlled trials have investigated the effect 
of OLZ augmentation of FLX in acute phase TRD, two of 
which were publised in a single paper by Thase et al.64 All 
studies were generally similar in design (Figure 1). Patients 
with non-psychotic major depression and a prior history of 
antidepressant failure (variously defined, as discussed below) 
received an open-label trial of antidepressant monotherapy 
during a pre-randomization (lead-in) phase. Individuals 
who failed to achieve a pre-specified threshold of symptom 
response during this open-label treatment phase were then 
eligible for randomization to double-blind acute phase 
treatment with OLZ + FLX or one of several active control 
conditions, including continuation treatment with the lead-
in phase antidepressant. The design features and key results 
of the pre-randomization and randomized acute treatment 
phases of each study are summarized in Tables 2 and 3, 
respectively.
The first randomized, controlled study of atypical 
antipsychotic drug augmentation of antidepressants for TRD 
compared the effects of FLX + OLZ, FLX monotherapy 
(FLX + placebo) and OLZ monotherapy (OLZ + placebo).58 
There is a paucity of long-term efficacy data for the use of 
FLX/OLZ combination therapy for TRD. In one single-arm 
study,67 a mixed sample of  560 patients with TRD (N = 145, 
defined as having history of past failure to respond to at 
least two trials of antidepressant treatment using agents 
of different pharmacological classes) and non-treatment 
refractory major depression (non-TRD, N = 407) received 
an open-label trial. Treatment resistance was confirmed 
by failure to achieve a partial response to open-label FLX 
(up to 60 mg/day) during the pre-randomization lead-in 
phase. Twenty-eight non-responders were then randomly 
assigned in a double-blind fashion to one of the three acute 
phase treatment conditions (see Table 3 for mean doses). 
Continuation of FLX monotherapy yielded no further 
improvement in depressive symptoms as measured by the 
Montgomery-Asberg Depression Rating Scale (MADRS),59 
the Hamilton Depression Rating Scale (HAM-D)60 and the 
Clinical Global Impressions-Depression subscale (CGI-D),61 Neuropsychiatric Disease and Treatment 2009:5 373
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while OLZ monotherapy achieved a modest benefit over FLX 
alone. The FLX/OLZ combination resulted in significantly 
greater improvement in depressive symptoms than FLX 
or OLZ alone (Table 3). The proportion of patients who 
achieved positive clinical response (50% improvement in 
MADRS scores at endpoint) was greater for the FLX/OLZ 
group (60%) compared with OLZ (0%) and FLX (10%) 
monotherapy groups. Pairwise comparisons of the proportion 
of those achieving positive clinical response were significant 
only for FLX/OLZ vs OLZ monotherapy, favoring combina-
tion therapy.
Four larger-scale randomized, double-blind multi-center 
studies investigating the effects of FLX/OLZ combina-
tion therapy were then completed.62–64 In the first study,62 
500 non-psychotically depressed patients with a prior history 
of failure to respond to a 4 week trial of SSRI treatment 
and prospective failure of open-label NTP (Table 2) 
were randomized to one of four treatment groups for the 
8-week acute phase study: FLX + OLZ, FLX monotherapy 
(FLX + placebo), OLZ monotherapy (OLZ + placebo), or 
continuation treatment with NTP (+ placebo) at the same 
dosage used during the pre-randomization lead-in phase 
(Table 3). The OLZ/FLX combination produced rapid 
antidepressant effect and statistically superior improve-
ment in MADRS scores compared with all monotherapy 
groups through the first four weeks of treatment; how-
ever, there were no significant differences between these 
groups at study endpoint. There were also no significant 
differences between the FLX + OLZ, FLX monotherapy, 
OLZ monotherapy, or NTP monotherapy groups in Hamilton 
Anxiety Scale (HAM-A)65 or Clinical Global Impressions-
Illness Severity subscale scores,61 or rates of categorical 
treatment response (27.5%, 28.9%, 19.3%, and 30.3%, 
respectively) or remission (16.9%, 13.3%, 12.9%, and 
18.2%, respectively), at study endpoint.
The second large-scale study compared the clinical 
effects of OLZ/FLX combination,63 FLX monotherapy, OLZ 
monotherapy, and VLFX monotherapy over 12 weeks in a 
cohort of non-psychotically depressed patients (N = 483) 
with a past history of failure to respond to a 6 week 
therapeutic SSRI trial and prospective failure of an open-
label lead-in trial of VLFX (Table 2). Again, there was 
Study endpoint:
8 weeks
Study endpoint:
8 weeks
Study endpoint:
12 weeks
Study endpoint:
8 weeks
Shelton et al.58 Shelton et al.62 Corya et al.63 Thase et al.64
Past history of
antidepressant
failure (N = 34)
Past history of
antidepressant
failure (N = 946)
Past history of
antidepressant
failure (N = 807)
Current 
antidepressant
failure (N = 1,313)
6-week open-
label trial of FLX
(20-60 mg)
7-week open-
label trial of NTP
(75-175 mg)
7-week open-label 
trial of VLFX 
(75-175 mg)
8-week open-label 
trial of FLX (50 mg)
Failure to
respond
Failure to
respond
Failure to
respond
Failure to
respond
Randomization
(N = 28)
Randomization
(N = 500)
Randomization
(N = 483)
Randomization
(N = 605)
FLX/OLZ FLX/OLZ FLX/OLZ FLX/OLZ
OLZ + PLC OLZ + PLC
OLZ + PLC FLX + PLC FLX + PLC OLZ + PLC
FLX (cont) + PLC FLX (cont) + PLC NTP (cont) + PLC VLFX (cont) + PLC
Double-blind
treatment
Double-blind
treatment
Double-blind
treatment
Double-blind
treatment
Figure 1 Basic design features of acute phase studies of combined fluoxetine and olanzapine (FLX/OLZ) in treatment resistant depression.58,62–64
Abbreviations: FLX, fluoxetine; FLX (cont), FLX treatment continued into double-blind study phase; FLX/OLZ, fluoxetine + olanzapine combination therapy; NTP, nortriptyline; 
NTP (cont), NTP treatment continued into double-blind study phase; PLC, placebo; VLFX, venlafaxine.Neuropsychiatric Disease and Treatment 2009:5 374
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significant early improvement associated with OLZ/FLX 
treatment, and significantly greater improvement in MADRS 
scores for OLZ/FLX over VLFX monotherapy (first 
6 weeks only) and FLX monotherapy (first 11 weeks only). 
At study endpoint, there was no evidence of a FLX/OLZ 
advantage over any antidepressant monotherapy group 
(Table 3). This included no significant differences between 
FLX + OLZ, FLX monotherapy, OLZ monotherapy, and 
VLFX monotherapy groups in rates of categorical treatment 
response (43.3%, 33.9%, 25.4%, and 50.0%, respectively) or 
remission (29.9%, 17.9%, 13.6%, and 22.4%, respectively) 
at study endpoint.
The final two studies were of identical design and were 
run concurrently (Study 1 and Study 2). Results were 
reported separately and as pooled data.64 Both studies 
were randomized, double-blind 8-week comparisons 
of FLX/OLZ combination therapy, FLX monotherapy 
(FLX + placebo) and OLZ monotherapy (OLZ + placebo) 
in a cohort of patients with non-psychotic major depression 
(N = 605, pooled data set). Eligibility was based on a past 
history of SSRI failure during the current depressive epi-
sode only, followed by prospective failure of an 8-week 
open-label FLX (50 mg/day) lead-in trial. In Study 1, there 
was no evidence of a superior antidepressive effect for 
FLX/OLZ combination treatment over either monotherapy 
group. However, in Study 2, the FLX/OLZ combination 
resulted in significantly greater improvement in MADRS 
scores, and in categorical response and remission rates, 
compared with both monotherapy groups at study endpoint. 
The pooled analysis of both projects revealed significantly 
greater improvement in MADRS scores, higher rates of 
categorical response (FLX + OLZ, 40.4%; FLX, 29.6%; 
OLZ, 25.9%) and remission (FLX + OLZ, 27.3%; FLX 
16.7%; OLZ 14.7%), and shorter time required for 25% of 
patients to achieve therapeutic responder status (FLX + OLZ, 
30 days; FLX, 55 days; OLZ, 53 days), compared with both 
monotherapy groups (Table 3). There were also advantages 
for FLX/OLZ over both antidepressant monotherapies in 
family and leisure functioning as measured by the Sheehan 
Disability Scale.66 There was no statistically significant 
advantage observed for work functioning.
results of long-term studies
There is a paucity of long-term efficacy data for the use of 
FLX/OLZ combination therapy for TRD. In one single-arm 
study,67 a mixed sample of 560 patients with TRD (N = 145, 
defined as having history of past failure to respond to at least 
two trials of antidepressant treatment using agents of different 
pharmacological classes) and non-treatment refractory major 
depression (non-TRD, N = 407) received an open-label 
trial FLX/OLZ (mean modal dose = 46.1 ± 20.7 mg/day of 
FLX/7.5 ± 3.5 mg/day of OLZ) for up to 76 weeks. There 
was a significant reduction in MADRS and CGI-S subscale 
scores as early as 0.5 weeks, followed by strong and continu-
ous reductions in these measures througout the remainder 
of the study in both TRD and non-TRD patients. At study 
endpoint, 61.6% of patients met categorical response criteria 
(50% reduction in MADRS scores), and 56.3% of patients 
achieved remission (MADRS scores of 8 on two consecu-
tive visits. Higher remission rates (60.7% vs 44.1%) and 
shorter time to remission were observed in the non-TRD 
compared with TRD sample. These results were tempered 
by relatively high droput rates. Only 177 (31.6%) of patients 
completed 52 weeks of treatment, and only 143 (25.5%) 
of patients completed the 76-week trial. In addition, of the 
patients who achieved remission, 12.1% of non-TRD and 
25.0% of TRD patients relapsed (defined as a MADRS score 
of 16 at any two visits following remission). More long-
term studies are needed.
Tolerability and safety
Safety and tolerability results across each of the acute-phase 
studies are summarized in Table 4. Rates of discontinuation 
due to treatment-emergent adverse effects (TEAEs) were 
greatest for FLX/OLZ- and OLZ monotherapy-treated 
patients. Because those who did not tolerate lead-in antide-
pressant medication were dropped prior to randomization, 
discontinuation rates tended to be lowest for drugs that were 
utilized during the lead-in phase and were continued during 
the double-blind treatment period.
Increases in body weight, total non-fasting cholesterol 
and serum prolactin (PRL) levels were greatest for the 
FLX/OLZ and OLZ groups. There was little change from 
baseline in any of these measures for the antidepressant 
monotherapy groups during double-blind treatment. The 
magnitude of increases in these measures between FLX/
OLZ and OLZ groups was generally similar. However, 
increases in total cholesterol were significantly greater for 
FLX + OLZ vs OLZ monotherapy in a pooled analysis of 
data from the 5 acute phase studies reviewed above.76 There 
were no significant differences for change in triglyceride 
levels between these two groups in the Thase et al64 study. 
There were no significant between groups differences in 
baseline to endpoint change in non-fasting glucose in the 
studies by Shelton et al62 and Thase et al;64 however, in 
both studies, the numerical increases in non-fasting glucose Neuropsychiatric Disease and Treatment 2009:5 377
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levels were greatest in the FLX/OLZ and OLZ groups 
relative to the antidepressant monotherapy groups. Similar 
increases in weight (+ 5.6 ± 6.6 kg) and non-fasting glucose 
levels were reported in the long-term open-label study by 
Corya et al67
Extrapyramidal side effects (EPS) were measured using 
the Simpson-Angus Scale (SAS),68 Barnes Akathisia Scale 
(BARS),69 and the Abnormal Involuntary Movement Scale 
(AIMS)70 in each of the reviewed studies. There were no 
significant between groups differences in EPS measures in 
the Shelton et al62 study. There were no significant changes in 
these measures from baseline in any of the treatment groups 
in the Corya et al63 study, or in the FLX/OLZ group in the 
Thase et al64 study. EPS measures for the FLX/OLZ group 
were reported as being similar to that of the OLZ group. In the 
long-term open-label study by Corya et al67 there were no 
significant increases in SAS, BARS or AIMS scores between 
baseline and the 76-week study endpoint. In the only study 
that assessed PRL response, FLX/OLZ was associated with 
significantly greater increases in PRL concentration than 
FLX, OLZ or NTP monotherapy.62
Discussion
Clinical issues
TRD is a common occurrence in clinical practice, and poses 
numerous challenges for the practicing clinician. While 
atypical antipsychotic augmentation of antidepressant medi-
cation was shown to be an effective strategy for patients with 
TRD in a recent meta-analysis of 10 randomized, double-
blind, placebo controlled trials,14 their exact place within the 
mélange of therapeutic options for managing TRD has not 
been precisely defined. For this to be determined, data from 
sequential treatment studies and/or head-to-head comparisons 
would be needed. The largest sequential investigation of 
therapeutic options in TRD to date, the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study, did not 
investigate the effects of atypical antipsychotic augmentation. 
Data from head-to-head comparison trials between FLX/OLZ 
and other interventions for TRD are not yet available. 
Nevertheless, based on clinical trial results that are currently 
available, the strongest clinical evidence supporting a role for 
atypical antipsychotic drugs as augmenters of  antidepressants 
in TRD exists for olanazapine, quetiapine and aripiprazole, at 
least for short-term, acute phase treatment.13,14,71–74 Of these, 
only aripiprazole is currently approved for this indication.
Our review of the literature, which focused on the effects 
of OLZ augmentation of FLX in TRD, also supports the 
short-term efficacy of this strategy, is consistent with a prior 
narrative review of FLZ + OLZ in TRD.75 Effectiveness of 
this combination appears to be particularly strong for those 
with an inadequate SSRI response and treatment resistance 
in the current depressive episode. Focusing on this sub-
population of patients has at least two advantages. First, 
the decision to augment antidepressant therapy with OLZ 
in actual clinical practice would be based on poor treatment 
response to antidepressant monotherapy in the current 
depressive episode, rather than having a history of poor 
antidepressant response in prior depressive episodes. Next, 
the consideration of only those subjects who met treatment 
failure criteria during the current depressive episode would 
guard against the inclusion of less treatment resistant cases 
in studies that focus specifically on intervention effects in 
TRD. This would result in a sample that is more representa-
tive of the TRD population encountered in clinical practice. 
Patients with TRD, defined in this more stringent manner, 
would also have a greater likelihood of achieving a more 
favorable clinical response to antidepressant augmentation 
compared with monotherapy. This position is supported by 
results of Shelton et al,58 Thase et al64 and the pooled analysis 
by Trivedi et al76 which focused on patients with TRD based 
on the current depressive episode only. All showed stronger 
effects of FLX/OLZ augmentation relative to antidepressant 
monotherapy than did individual large-scale studies that used 
a less stringent definition of TRD.62,63
Available evidence of effectiveness FLX + OLZ in TRD 
is similar to the published data describing the combination’s 
effectiveness for the short-term acute-phase treatment of 
depression in patients with bipolar I disorder.77,78 In two 
randomized, controlled studies, FLX + OLZ resulted in 
greater 8-week improvement in depressive symptomatology 
compared with placebo and OLZ monotherapy,79 and greater 
7-week improvement than lamotrigine.78 In addition, combi-
nation therapy with FLX + OLZ was associated with higher 
remission rates than placebo or OLZ monotherapy,77 and a 
similar remission rate as lamotrigine.78 In one small placebo-
controlled study comparing the effects of FLX + OLZ, OLZ 
monotherapy, FLX monotherapy and placebo in depressed 
patients with bipolar I or II disorder, there were significant 
reductions in depressive symptoms for the entire cohort; 
however, the study was under-powered to detect differences 
between treatment groups.80 In published studies of bipolar 
depressed patients, FLX + OLZ was generally well tolerated, 
with limited safety data suggesting that FLX + OLZ combina-
tion therapy was associated with weight gain and lipid and 
prolactin level elevation similar to that of OLZ monotherapy. 
As is the case with TRD, long-term safety and effectiveness Neuropsychiatric Disease and Treatment 2009:5 379
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data in bipolar patients are generally lacking. FLX + OLZ 
combination therapy was associated with significantly greater 
improvement in depressive symptoms than lamotrigine in a 
25-week double blind extension of the 7-week acute phase 
study by Brown et al.78,79 However, FLZ + OLZ was associ-
ated with more frequent weight gain and significantly higher 
incidence of clinically significant hypercholesterolemia 
(240 mg/dL) and weight gain (7% increase in weight 
from baseline) at the 25 week endpoint.79 Overall, the state 
of the available evidence for FLX + OLZ therapy in bipolar 
depression is similar to that of the combination in TRD, with 
encouraging results shown in short-term acute phase studies, 
but limited longer-term data.
Enthusiasm is thus tempered by several unanswered ques-
tions regarding the use of FLX/OLZ augmentation in TRD. 
The optimal augmenting dose of OLZ has not been estab-
lished, though anecdotal reports and uncontrolled evidence 
suggest that the target dose may be lower (2.5 to 10 mg) 
than those used in the treatment of schizophrenia or bipolar 
disorder.81,82 The long-term efficacy and safety profile of 
FLX/OLZ in TRD has also not been established. There have 
been no controlled investigations longer than 12 weeks to 
date. As such, there are also no studies focused on the ques-
tion of how long OLZ augmentation of FLX is required 
among patients who respond acutely to the combination.
The paucity of long-term studies is also of vital clinical 
interest because of concerns about body weight gain and 
dysmetabolic effects that are associated with OLZ. Of the 
antipsychotic drugs, OLZ is among the most orexigenic 
and, with the exception of clozapine, is associated with the 
greatest short-term weight gain and longer-term risk of hyper-
glycemia, diabetes, and atherogenic dyslipidemia.83–85 These 
metabolic risks must be carefully considered when deciding 
among the varied options available for augmentation of anti-
depressants in TRD. Apart from the obvious long-term health 
concerns, individuals with MDD are in physically poorer 
health than the general population86 and therefore comprise 
a patient sub-population that is already at risk for profound 
cardiovascular morbidity and early mortality. Indeed, major 
depression has been identified as an independent risk factor 
for coronary artery disease and premature death due to 
cardiovascular causes.87–89 As is the case with schizophrenia 
and bipolar disorder, psychiatric illnesses that are associated 
with considerable physical health burden and early mortality 
due to cardiovascular disease,90,91 use of OLZ for patients 
with major depression requires close metabolic monitoring 
and follow-up. The stringency of such monitoring should 
generally be the same that used for OLZ treatment of bipolar 
disorder and schizophrenia, even if lower doses of OLZ are 
shown to be effective for antidepressant augmentation.
Characteristics and implications  
of study design and execution
The definition of TRD is a matter of ongoing debate, and 
numerous and varying criteria have been used to defined TRD 
samples in clinical trials.92 To improve uniformity, several 
definitional models have been proposed, a detailed review of 
which will not be provided here. The interested reader is referred 
to several excellent reviews.93–95 For purposes of the current 
discussion, some design features and issues in study execution, 
many of which focus on sample selection and study definitions 
of TRD, may have led to the inclusion of less-treatment resistant 
depressed patients. This could have introduced bias toward null 
findings in some of the reviewed studies.
For example, two of the reviewed studies based their 
definition of TRD, in part, on a history of failure not confined 
to the current depressive episode.62,63 Only the studies by 
Shelton et al58 and Thase et al64 randomized patients that had 
both a retrospective and prospective lead-in antidepressant 
failure in the current depressive episode. Only the Thase 
et al64 group randomized patients that had both a retrospective 
and prospective lead-in antidepressant failure in the current 
depressive episode only. Planned sub-group analyses of 
subjects in the Shelton et al62 and Corya et al63 studies who met 
both retrospective and prospective TRD inclusion criteria for 
the current depressive episode revealed a more marked treat-
ment effect for FLX/OLZ. In the Corya et al63 study, improve-
ment in MADRS at study endpoint was significantly greater for 
FLX/OLZ compared with FLX alone in this patient subgroup. 
A pooled analysis of data from all of the above reviewed 
acute-phase studies was performed by Trivedi et al76 which 
focused on only those subjects with a history of antidepressant 
non-response in the current depressive episode (N = 1146). 
FLX/OLZ was associated with significantly greater 8-week 
improvement in MADRS scores (–13.0 vs –8.6 vs –8.2) and 
higher rates of remission (25.5% vs 17.3% vs 14.0%) compared 
with FLX or OLZ monotherapy.76
Second, although a 4- to 6-week time interval for lead-
in phase treatment could be considered generally adequate, 
many patients may require longer than this to adequately 
respond to antidepressant monotherapy,96 a situation that may 
be even more problematic for drugs that require slower or 
more prolonged titration to therapeutic doses. These factors 
may have been particularly relevant for the Shelton et al62 and 
Corya et al63 studies, both of which utilized antidepressant 
medications during the lead-in phase that required titration to Neuropsychiatric Disease and Treatment 2009:5 380
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therapeutic doses (NTP and VLFX, respectively). Assuming 
that dosage adjustments were made during the first week 
even after achieving initial target doses, this would have left 
approximately 6 weeks of lead-in antidepressant treatment 
at adequate dosage. This time interval would not be suffi-
cient to exclude late responders who, by definition, are not 
treatment-resistant but would have still been included in the 
double-blind acute treatment phase of these studies.
Third, investigators in the Shelton et al62 and Corya 
et al63 studies were not blinded to the double-blind acute 
phase entry criteria (reduction of 30% in MADRS scores) 
which, as pointed out by the study authors, may have led to 
unconscious bias toward continued treatment and random-
ization via an under-rating of MADRS scores at the end of 
the lead-in phase. The lower than expected rates of partial 
treatment response at the end of the lead-in phase of both 
of these studies (18% and 26%, respectively) support this 
hypothesis; however, response rates for individuals with 
treatment resistant depression would also be expected to be 
low. In the study by Thase et al64 investigators were blinded 
to the double-blind acute phase study entry criteria. As such, 
the potential limitations posed by lack of blinding to acute 
phase study criteria do not apply to this study.
Fourth, in each of the reviewed studies, some patients 
who were eligible for double-blind acute phase treatment 
were re-randomized to the same antidepressant medication 
that they received during the lead-in period. These individuals 
would have received up to 15 weeks of NTP treatment in the 
Shelton et al62 study, up to 19 weeks of VLFX treatment in 
the Corya et al63 study, and up to 16 weeks of FLX treatment 
in the Thase et al64 study, thus causing an imbalance in study 
design and possible bias in favor of NTP, VLFX, or FLX, 
respectively. Finally, none of the reviewed studies included a 
placebo, as it was deemed unethical to deny active treatment to 
patients with refractory depression. Lack of a placebo group, 
however, makes it difficult to rule out non-pharmacological 
causes of clinical improvement across groups.
Summary and conclusions
TRD represents a clinical challenge for which more effective 
treatments are urgently needed. The combination of FLX and 
OLZ has shown considerable promise in short-term, acute phase 
studies; however, little is known about the relative effectiveness 
of FLX/OLZ augmentation compared with other augmenting 
or combination strategies for TRD. Several questions remain 
concerning the optimal dosing and required duration of OLZ 
in combination with FLX for patients with TRD, and little is 
known about the long-term efficacy, tolerability and safety of 
this combination. This includes lack of data regarding long-term 
effects of FLX/OLZ on surrogate markers of cardiovascular 
risk (weight gain, dysglycemia, atherogenic dyslipidemia) and 
important clinical endpoints (eg, development of diabetes and 
serious cardiovascular disease). Future studies of compara-
tive effectiveness of FLX/OLZ augmentation and other forms 
of combination therapy for TRD are needed in order to best 
determine its place among existing treatment options, either in 
the form of head-to-head comparisons with other TRD treat-
ment options or as a therapeutic option in sequential treatment 
studies of patients with major depression.
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